CAS: 267875-30-9; 2-Cyano-4-Methyl-5-Nitropyridine
该化合物是一种硝基丙烯衍生物,具有硝基丙烯功能组,通常用作有机合成和制药研究的多用途中间体,其结构特征,包括电子退出的硝基硝基和硝基三烯组,使其对构建异环化合物和促进核循环替代反应很有价值.4级的甲基组增强了其在有机溶剂中的溶解性,改善了不同合成途径的再活性.该组因其能成为生物活性分子的前体,在标准条件下的稳定确保了可靠的处理和储存.
- 英文名称2-Cyano-4-Methyl-5-Nitropyridine
- 中文名称2-氰基-4-甲基-5-硝基吡啶
- IUPAC名称4-methyl-5-nitropicolinonitrile
- 其它别名2-Cyano-4-Methyl-5-Nitropyridine; 4-Methyl-5-Nitropyridine-2-Carbonitrile; 4-Methyl-5-Nitropicolinonitrile; 4-Methyl-5-Nitro-Pyridine-2-Carbonitrile; 2-Cyano-5-Nitro-4-Picoline; 2-Pyridinecarbonitrile, 4-Methyl-5-Nitro-
- CAS编号267875-30-9
- MFCD编号:MFCD07368385
- 分子式:C7H5N3O2分子量:163.13
- 产品CID: 1246654
- 产品分类有机原料→分子砌块→芳杂环类化合物→吡啶类化合物
相似化合物
5832-43-9 1074-99-3 1074-76-6物理性质
MSDS等安全信息
上下游产品
dicyanozinc 2-bromo-4-methyl-5-nitropyridine 2-hydroxy-4-methyl-5-nitropyridine 4-methyl-5-nitropyridin-2-yl trifluoromethanesulfonate ethyl 4-methyl-5-nitropyridine-2-carboxylate 5-amino-4-methylpyridine-2-carbonitrile合成工艺路线路线简述
📜2-羟基-4-甲基-5-硝基吡啶置于四(三苯基膦)钯,三溴氧磷体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 6.0H,反应生成2-氰基-4-甲基-5-硝基吡啶
参考文献:Plasma Kallikrein Inhibitors And Uses Thereof
标题:Plasma Kallikrein Inhibitors And Uses Thereof
摘要:本发明提供了作为血浆激肽酶抑制剂并具有相同理想特性的化合物及其组合物.
海关参考信息
- 2933310010-吡啶
2904209090-其他仅含硝基或亚硝基衍生物
2926909090-其他腈基化合物
2939800000-其他生物碱 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-7468375-B2
优先权日:2004-04-26
标题:Inhibitors of the HIV integrase enzyme
发明人：DRESS KLAUS RUPRECHT; HU QIYUE; JOHNSON TED WILLIAM; PLEWE MICHAEL BRUNO; TANIS STEVEN PAUL; WANG HAI; YANG ANLE; YIN CHUNFENG; ZHANG JUNHU
权利人:PFIZER
摘要:The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIVâ€?) integrase enzyme.
专利号:US-2009170846-A1
优先权日:2005-10-03
标题 :Inhibitors of the hiv integrase enzyme
发明人：DRESS KLAUS RUPRECHT; PLEWE MICHAEL BRUNO; JOHNSON TED WILLIAM; TANIS STEVEN PAUL; TRAN KHANH TUAN
权利人:PFIZER
摘要:The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus “HIVâ€? integrase enzyme. Formula (I).
